Triple
T22717587
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Genzyme |
E561775
|
entity |
| Predicate | formerName |
P65
|
FINISHED |
| Object | Genzyme Corporation |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Genzyme Corporation | Statement: [Genzyme, formerName, Genzyme Corporation]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Genzyme Corporation Context triple: [Genzyme, formerName, Genzyme Corporation]
-
A.
Genzyme
chosen
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
B.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
C.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
D.
BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
-
E.
Amgen
Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454fc984819088213b58ee87a002 |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1790ecbc48190926d16b20b674dbd |
completed | April 29, 2026, 3:20 a.m. |
Created at: April 17, 2026, 3:19 p.m.